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CYP2C8 and CYP2C9 are involved in the inactivation of several non-steroidal anti-
inﬂammatory drugs, including ibuprofen. CYP2C9 is the major form in human liver whereas
CYP2C8 has been proposed to be the main CYP2C enzyme in fetal liver. The protein
expression of CYP2C9 in the ﬁrst trimester is low, only about 1% of the adult values,
whereas the mRNA levels of CYP2C8/9 have not been determined at the fetal stage. In this
study themRNAexpression levels of CYP2C8 andCYP2C9were determined in 20 adult and
60 fetal liver tissue specimens. The expression proﬁles in fetal kidneys (n = 43), adrenals
(n = 46), and lungs (n = 37) were also determined. Moreover the activity against ibuprofen
hydroxylation was determined in fetus and adult liver microsomes. Adult liver samples
expressed 140 and 400 times higher levels of CYP2C8 and CYP2C9 mRNA, respectively,
as compared to fetal liver samples. Consistent with this, the hydroxylation of ibuprofen was
40 times higher in the adult liver microsomes. Hepatic CYP2C8 mRNA was three times
more abundant than CYP2C9 mRNA in the fetus. Moreover, CYP2C8 were consistently
expressed in all fetal tissues investigated, whereas CYP2C9 gene expression was conﬁned
to the liver in fetuses. Our results indicate that CYP2C8 plays amore important physiological
role than CYP2C9 in the ﬁrst trimester.
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INTRODUCTION
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are indicated
for the treatment of common conditions such as pain, headache,
cold, and ﬂu. Many of the NSAIDs are available without a pre-
scription and consequently they are one of the most commonly
used drugs during pregnancy (Werler et al., 2005; Ofori et al.,
2006). Thus, ibuprofen has been reported to be used among
pregnant women in about 15% (Glover et al., 2003; Werler et al.,
2005). NSAIDs cross the placenta but what and if any effects
are exerted in fetal tissue is not known. It has been proposed
that NSAIDs, early in pregnancy, increase the risk of having
a child with congenital anomalies and the risk of spontaneous
abortion (Ofori et al., 2006; Hernandez et al., 2012). The effects
on the ductal artery warrant a caveat against its use close to
delivery.
Several of the NSAIDs, including ibuprofen are metabolized
by CYP2C8 and CYP2C9. In fact, about 20% of all clinically
important drugs are metabolized by members of the CYP2C
subfamily (Goldstein, 2001). Additionally both CYP2C8 and
CYP2C9 are involved in the metabolism of endogenous substrates
such as epoxyeicosatrienoic acids (EETs) and retinoic acids (RAs;
Marill et al., 2000; Zeldin, 2001). Despite the structure homology,
CYP2C8 and CYP2C9 do not share many substrates, a few are
described in the literature including ibuprofen (Totah and Ret-
tie, 2005). CYP2C9 is the major form in human liver (Goldstein
and de Morais, 1994) whereas CYP2C8 has been proposed to be
the main CYP2C enzyme in fetal liver (Hakkola et al., 1994). The
protein expression of CYP2C9 in the ﬁrst trimester is low, only
about 1% of the adult values (Hines, 2007). Hines also described
an increase in CYP2C9 expression during the third trimester to
10% of the adult values (Hines, 2007).
Few studies have determined themRNA expression of CYP2C8
and CYP2C9 in fetus. The purpose of the current study was to
determine and compare intra- as well as inter-individual degrees
of mRNA expression of CYP2C8 and CYP2C9 in specimens of
human fetal (n = 60) and adult (n = 20) livers, as well as the
ibuprofen hydroxylation activity in pooled liver microsomal sam-
ples. The mRNA expression proﬁles of the CYP2C8/9 were also




Human adult liver specimens (n = 20) were collected between
1997 and 2001 as previously described (von Bahr et al., 1980). The
study cohort used here included 20 adult livers of male (n = 9),
female (n = 10), or unknown sex (n = 1) fromCaucasian (n = 17)
and Asian (n = 3) patients between 30 and 75 years of age.
Human fetal liver (n = 60), adrenal (n = 46), kidney (n = 43),
and lung (n = 37) specimens from 60 fetuses with unknown
ethnicity were obtained at legal abortions performed for socio-
medical reasons at the Karolinska University Hospital between
year 2000–2003. The fetal tissues were excised and immediately
frozen in liquid nitrogen and stored at −70◦C within 2 h. The
study was approved by the Ethics Review Board in Stockholm and
by the National Board of Health and Welfare.
The gestational age of the fetuses were determined by crown-
rump length and ranged from 5 to 12 weeks (median age
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10.2 weeks). Thematernal age ranged from 18 to 43 years (median
age 29). The sex of the fetuses was not determined at collec-
tion since this is not normally documented at abortions and may
even be difﬁcult to determine at this early gestational age. None
of the women reported any chronic or acute diseases, regular
drug use, or drug abuse. Smoking was reported in 22 women
(37%), non smoking in 21 (35%), whereas for 17 there were no
reports.
RNA EXTRACTION AND cDNA SYNTHESIS
Total RNA from 5 to30mg of fetal tissue samples and 200mg adult
liver tissue was prepared using AllPrep DNA/RNA Mini Kit and
RNeasy kit (Qiagen, Hilden, Germany), respectively, according
to the manufacturer’s protocols. RNA (0.5 μg) was reverse tran-
scribed into cDNA with random hexamers using SuperScript®III
First Strand Synthesis Super Mix (Invitrogen) according to the
manufacturer’s instruction, and diluted 10 times.
QUANTITATIVE REAL-TIME PCR
Quantitative Real-Time PCR was performed using the 7500 Fast
Real-Time PCR System (Applied Biosystems, Foster City, CA,
USA). Each PCR reaction mixture had a ﬁnal volume of 15 μl
containing (2×) TaqMan PCR Master Mix (Applied Biosys-
tems), (20×) premade primer and probe mix for CYP2C8 or
CYP2C9 (Hs00946140_g1 and Hs01682803_mH,Applied Biosys-
tems), and 1 μl cDNA template. 18S (PN 4310893E, Applied
Biosystems) was chosen as an endogenous housekeeping control
gene.
The real-time PCR proﬁle for the assay was: 50◦C for 2 min,
followed by activation at 95◦C for 10 min and 40 cycles of denatu-
ration at 95◦C for 15 s and annealing/elongation at 60◦C for 1min.
Each sample was analyzed in duplicates and no-template controls
were included in each experiment. The cycle threshold (Ct) val-
ues provided from the real-time PCR were analyzed using the
2−Ct method (Livak and Schmittgen, 2001). One sample was
used as calibrator and the mRNA expression is expressed relative
the endogenous housekeeping control gene.
CYP2C9 ENZYME ACTIVITY IN FETAL AND ADULT LIVER MICROSOMES
A pool each of fetal liver microsomes (n = 4, 10–12 weeks
of age) and adult liver microsomes (n = 4, 55–68 years of
age) were prepared as described previously (Hakkola et al.,
1994). Protein concentration in liver microsomes was measured
according to Lowry et al. (1951). The incubation method was
based on Chang et al. (2008). Brieﬂy, S-ibuprofen was incu-
bated with human liver microsomes (1 mg/mL protein equiva-
lent) in potassium phosphate buffer 0.1 M pH 7.4 and MgCl2
2.5 mM for a total volume of 200 μL. After a pre-incubation
at 37◦C for 3 min. NADPH (2.4 mM) was added and the
mixture was incubated at 37◦C for 20 min. The reaction was
stopped with 100 μL glacial acetic acid and the S-ibuprofen
and 2-OH-ibuprofen were extracted by liquid–liquid extraction
using 2 mL x 4 mL ethyl acetate/heptanes (50:50, v/v). The
organic phase was isolated, evaporated to dryness and reconsti-
tuted in 50 μL acetonitrile:H2O (20:80, v/v) prior to analysis by
liquid chromatography coupled to mass spectrometry detection
(LC–MS).
The LC–MS analysis was performed on an Agilent 1100 system
from Agilent Technologies (Santa Clara, CA, USA) equipped with
a Kinetex C18 column (50 mm x 2.1 mm, 2.6 μm) from Phe-
nomenex (Torrance, CA, USA). A gradient method was used with
formic acid 25 mM and acetonitrile, the ﬂow was 0.5 mL/min,
the injection volume 1–2 μL and the run time was 5 min. In
order to facilitate the determination, three ions were used for the
detection of ibuprofen (m/z 207 and 224 in the positive mode
and m/z 205 in the negative mode) and summed up for calcu-
lation. Ratios between ions were compared to control the peak
purity. The same strategy was applied for 2-OH-ibuprofen with
m/z 205 and 240 in the positive mode and m/z 221 in the negative
mode.
Incubations were prepared in triplicates and the activity of one
of the adult sample was used as a calibrator.
DATA ANALYSIS
Statistical analysis was performed using GraphPad Prism software
version 4.0 (San Diego, CA, USA). The mRNA expressions in
adult samples compared to fetal samples were compared using the
Mann–Whitney U-test. Kruskal–Wallis followed by Dunn’s test
was used for the tissue comparison of mRNA expression. The
correlation analyses were performed using the Spearman rank
method. Values of p < 0.05 were considered to be signiﬁcant.
Values are presented as mean ± SD.
RESULTS
CYP2C8 AND CYP2C9 mRNA EXPRESSION IN ADULT AND FETAL LIVER
The mRNA expression of CYP2C8 and CYP2C9 was studied in
20 human adult and 60 fetal liver specimens using quantitative
real-time PCR. CYP2C8 mRNA expression was detectable in 96%
(n = 58) of the fetal liver samples and in 90% (n = 18) of the
adult liver samples. Signiﬁcantly higher levels of CYP2C8 were
observed in the adult liver samples (mean 136.1 ± 122.0) com-
pared to the fetal liver samples (mean 0.95 ± 0.64), p < 0.0001.
The mRNA expression of CYP2C8 in fetuses was 0.70% of
the adult values (143 times higher in adult compared to fetus;
Figure 1A).
ThemRNAexpressionof CYP2C9wasdetected in 92%(n=55)
of the fetal liver samples and in 90% (n = 18) of the adult liver
samples. Signiﬁcantly higher expression of CYP2C9 was detected
in the adult liver samples (mean 1385 ± 1499) compared to the
fetal liver samples (mean 3.54 ± 3.11), p < 0.0001. The mRNA
expression of CYP2C9 in fetuses was 0.25% of the adult values
(396 times higher in adult compared to fetus; Figure 1B).
The ratio between CYP2C8 and CYP2C9 was 4.5 in fetal livers
and 1.5 in adult livers demonstrating three times higher expres-
sion of CYP2C8 compared to CYP2C9 in fetuses than in adults
(Figure 2).
A signiﬁcant difference between the mRNA expression of
CYP2C8 (mean 0.95 ± 0.64) compared to CYP2C9 (mean
0.29 ± 0.25) was observed in liver from fetus (p < 0.0001) but
no difference between these mRNA expressions in adult liver was
found (CYP2C8 mean 136 ± 122, CYP2C9 mean 112 ± 121).
The mRNA expression of CYP2C8 and CYP2C9 were signiﬁ-
cantly correlated in liver in both adults (r = 0.8962, p < 0.0001)
and fetuses (r = 0.3844, p = 0.0038; Figures 3A,B).
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FIGURE 1 | Relative mRNA expression of (A) CYP2C8 and (B) CYP2C9
in liver from human fetuses (n = 60) and adults (n = 20): Significantly
higher levels (143 times) of (A) CYP2C8 were observed in the adult
liver samples, p < 0.0001 and significantly higher levels (396 times) of
(B) CYP2C9 were observed in the adult liver sample, p < 0.0001.
FIGURE 2 |The ratio of the mRNA expression of CYP2C8 compared to
CYP2C9 in fetal and adult liver.The ratio between CYP2C8 and CYP2C9
was calculated to 4.5 in fetus and 1.5 in adult demonstrating three times
higher expression of CYP2C8 compared to CYP2C9 in fetus than in adult.
***p < 0.001.
The relationship between smoking/maternal age/gestational
age and themRNA expression of CYP2C8/CYP2C9was also inves-
tigated. The only signiﬁcant correlation found was between the
fetal hepatic CYP2C9 mRNA expression and the gestational age of
the fetus (r = 0.3060, p = 0.0364).
FIGURE 3 | Relative mRNA expression of CYP2C8 correlated with the
relative mRNA expression of CYP2C9 in (A) adult liver and (B) fetal
liver.The correlation study shows a signiﬁcant association between the
mRNA expression of CYP2C9 and CYP2C8 in (A) adult liver (r = 0.8962,
p < 0.0001) and in (B) fetal liver (r = 0.3844, p = 0.0038).
CYP2C9 ENZYME ACTIVITY IN LIVER MICROSOMES FROM ADULT AND
FETAL LIVERS
The formation of 2-OH-ibuprofen was analyzed using LC–MS
after incubation with S-ibuprofen for 20 min. The hydroxylation
activity was 40 times higher in the adult microsome pool sample
(n = 3) as compared to the fetal liver microsome pool sample
(n = 3), p = 0.03, (Figure 4).
FETAL EXTRA-HEPATIC CYP2C8 AND CYP2C9 mRNA EXPRESSION
The mRNA expression of CYP2C8 and CYP2C9 were analyzed in
liver (n = 60), kidney (n = 43), adrenal (n = 46), and lung (n = 37)
tissues from fetuses.
CYP2C8 mRNA expression was detected in all of the extra-
hepatic tissue samples from fetuses. CYP2C9 mRNA expression
was only detected in one of the kidney samples, two of the adrenal
samples, and in none of the lung samples.
Signiﬁcant differences in mRNA expression of CYP2C8
between the different organs were demonstrated with signiﬁcantly
higher expression in lung compared to kidney (p < 0.05), adrenal
(p < 0.01), and liver (p < 0.001). The relative mRNA levels were
in liver (mean = 1.98 ± 1.34), kidneys (mean = 3.38 ± 1.42),
adrenals (mean = 3.29 ± 1.78), and lungs (mean = 4.58 ± 1.79).
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FIGURE 4 | Relative activity of 2-OH-ibuprofen in fetal and adult liver
samples. Human liver microsomes obtained from pooled adult (n = 3) and
fetal (n = 3) livers were incubated with ibuprofen. The analyses were
performed in triplicates. The formation of 2-OH-ibuprofen was signiﬁcantly
higher in adult compared to fetal samples, (p = 0.03). *p < 0.05.
When performing the statistical analysis the samples were paired,
thus the results in the ﬁgure represents the results from tissues
from 32 fetuses (Figure 5).
Since the expression of CYP2C9 was found only in one kid-
ney, two adrenal specimens, and in none of the lung samples no
statistical analysis was performed.
The relationship between the mRNA expression of CYP2C8
and different organ/the age of the mother/the gestational age of
the fetus/smoking was investigated. No signiﬁcant correlations or
differences were found (data not shown).
FIGURE 5 | Relative CYP2C8 mRNA expression in liver, adrenal, kidney,
and lung from human fetuses (n = 60). CYP2C8 mRNA expression was
detected in all of the extra-hepatic tissue samples with signiﬁcantly higher
expression in lung compared to kidney, adrenal and liver. *p < 0.05,
**p < 0.01, ***p < 0.001.
DISCUSSION
Here we show that CYP2C8 and CYP2C9 gene expression in
human fetus is very low, 0.70 and 0.25% of the expression found
in adult livers. This result is in agreement with previous ﬁndings
reporting that CYP2C9 protein in the ﬁrst trimester is about 1%
of the protein concentration in adults (Hines, 2007). Interestingly,
hepatic CYP2C8 was approximately three times more abundant in
the fetuses than CYP2C9 transcripts. This in concordance with a
previous study proposing that CYP2C8 is the main CYP enzyme
in the fetal liver (Hakkola et al., 1994). The situation in adult livers
appears to be the opposite, where CYP2C9 is expressed at twofold
higher level than CYP2C8 (Lapple et al., 2003).
In addition to CYP2C8 mRNA being more abundant than
CYP2C9 mRNA in the fetal liver, CYP2C8 was found in all
extra-hepatic fetal specimens examined. This was not the case
for CYP2C9, which was only detectable in isolated samples of
kidney and adrenals, and absent in the fetal lung. The reason
for CYP2C8 to be more abundant in the early pregnancy is
not known. It is possible that CYP2C8 may be required in the
metabolism of endogenous compounds such as retinoic acids,
known to be more speciﬁc for CYP2C8 (Marill et al., 2000),
and hence protect the human fetus against retinoic acid-induced
embryotoxicity.
CYP2C9 gene expression in the liverwas the only transcript that
correlated with gestational age. Koukouritaki et al. (2004) showed
that CYP2C9 protein expression increases with advancing gesta-
tion. In the third trimester the CYP2C9 protein expression has
increased from 1% in ﬁrst and second trimester to reach 10% of
adult levels. It is conceivable that CYP2C9 expression is induced
and more important later in pregnancy. Furthermore it has been
shown that CYP2C9 are further induced after birth (Hines, 2007).
The co-expression of hepatic CYP2C8 and CYP2C9 in the
fetuses and adults, but not in the extra-hepatic specimens investi-
gated, indicates that they may be transcriptionally regulated to
some degree by the same liver speciﬁc factors throughout the
development. HNF4, CAR, PXR, and AHX are transcription fac-
tors known to be involved in the hepatic expression of several CYPs
including CYP2C8/9. A strong correlation between CYP2C9 and
CYP2C8 mRNA levels in adult livers has also been observed by
others (Wortham et al., 2007; Naraharisetti et al., 2010).
A large inter-individual variation in CYP2C8/9 gene expres-
sion in both the adults (70- and 220-fold, respectively) and fetal
(approximately 20-fold) subjects was observed. In adults the
inter-individual variation for CYP2C8 and CYP2C9 expression
has been found to be in the same range as observed here, in
Naraharisetti et al. (2010), Rodriguez-Antona et al. (2001), and
Wortham et al. (2007), whereas this is the ﬁrst time the inter-
individual variation in early pregnancy has been studied. The large
variability in CYP2C8/9 expression may be determined by hor-
monal status, diet, smoking, and drug exposure. However, there
was no correlation between sex and CYP2C8/9 mRNA expression
in the adult samples. Sex was not determined at the collec-
tion of fetus specimens. We could not discern any correlation
with maternal smoking and CYP2C8/9 expression in this
study.
The mRNA levels of CYP2C8/9 have been shown to correlate
with the total activity (Rodriguez-Antona et al., 2001; Yang et al.,
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2010). In agreement with our gene expression results, the activity
was lower in a pooled fetal sample compared to the activity in
the adult sample. Ibuprofen is extensively metabolized to hydrox-
ylated metabolites. Ibuprofen preparations contain a mixture of
R-(–)- and S-(+)- ibuprofen. S-Ibuprofen is hydroxylated to 2-
OH-ibuprofen mainly by CYP2C9, whereas CYP2C8 is the main
enzyme involved in the hydroxylation of R-ibuprofen (Hamman
et al., 1997). Here we analyzed the 2-OH-ibuprofen formation
and consequently mainly the CYP2C9 activity. Minor contribu-
tion of other CYPs could be the reason why the difference in
CYP2C9 activity between adult and fetus was not as large as
the difference in mRNA expression. CYP3A4 has been shown
to be involved in S-ibuprofen 2-OH-ibuprofen activity in vitro
(Chang et al., 2008), whereas the involvement of the speciﬁc fetal
CYP3A7 enzyme has not been studied. As expected, a disadvan-
tage with this study is that the fetal specimens collected were not
sufﬁciently large to conduct activity measurements on individual
samples.
The embryonic period studied here (5–12 weeks) is the most
crucial in terms of structural malformations. Drug exposure dur-
ing this time may result in congenital malformations and/or
growth abnormalities (Blumenfeld et al., 2010). In view of the
increasing use of prescribed drugs and OTC drugs in pregnancy
more knowledge in fetal drugmetabolism enzyme is needed to cast
light onmechanisms of drug and xenobiotic induced fetal toxicity,
teratogenicity, and pharmacological response to drug treatment in
pregnancy.
In conclusion, we have shown that CYP2C9 and CYP2C8
mRNA levels, as well as CYP2C9 activity are higher in adult liv-
ers as compared to fetal livers and that the tissue distribution of
CYP2C8 and CYP2C9 is widely different. Our results indicate that
CYP2C8 plays a more important physiological role than CYP2C9
in the ﬁrst trimester, since it was more abundant in the liver and
were found consistently in extra-hepatic tissues such as adrenal,
kidney, and lungs.
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